Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ODIXa-DVTA: Rivaroxaban Dose Finding in DVT
NCT00839163Phase 2Completed
- Sponsor
- Bayer
- Start
- Mar 2004
- Primary completion
- Oct 2005
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 2, randomised, single-blind trial of rivaroxaban in deep vein thrombosis (DVT) (5 arms), sponsored by Bayer. Primary endpoint: Response to treatment as determined by a Complete Compression Ultra sound (CCUS) at 21 days. Started Mar 2004; status: completed.
02
Drugs
rivaroxaban
03
Conditions
deep vein thrombosis (DVT)
Beyond the preview
Go deeper on NCT00839163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00839163.